Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Findings from a pioneering study reveal that administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function.
The September 14 workshop brought together multidisciplinary experts in extracellular vesicles – cell-secreted nanoparticles that mediate cell-cell communication.
Scientists have identified a protein in the visual system of mice that appears to be key for stabilizing the body’s circadian rhythms by buffering the brain’s response to light.
Researchers at Louisiana State University have identified a new mechanism that protects against the excessive oxidative stress that precedes the development of neurodegenerative diseases of the brain and eye.
In a comparative analysis across animals of the many cell types in the retina, researchers concluded that most cell types have an ancient evolutionary history.
Researchers at the National Eye Institute have mapped the 3D organization of genetic material of key developmental stages of human retinal formation, using intricate models of a retina grown in the lab.
This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD).
Wilmer Eye Institute researchers at Johns Hopkins Medicine have found how oxidative stress and the protein HIF-1 contributes to what kind of age-related macular degeneration (AMD) a patient could develop.